PubRank

Ingo K Mellinghoff

Author PubWeight™ 128.01‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A 2007 18.83
2 High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007 12.68
3 IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012 8.66
4 IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012 7.95
5 Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 2008 5.54
6 An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013 5.10
7 A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. Nat Med 2012 4.64
8 Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med 2006 4.63
9 Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2005 4.44
10 Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. PLoS Comput Biol 2006 3.39
11 Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res 2006 3.31
12 Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 2009 3.14
13 AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 2003 2.88
14 Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol 2008 2.75
15 Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell 2009 2.73
16 Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov 2012 2.61
17 Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nat Genet 2013 2.59
18 Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet 2009 2.51
19 Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell 2007 2.43
20 EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal 2009 2.23
21 The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci U S A 2009 2.09
22 PTEN dosage is essential for neurofibroma development and malignant transformation. Proc Natl Acad Sci U S A 2009 2.07
23 Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor. Proc Natl Acad Sci U S A 2006 1.93
24 mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab 2013 1.86
25 A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. Proc Natl Acad Sci U S A 2010 1.81
26 An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov 2011 1.77
27 Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET. J Nucl Med 2005 1.63
28 IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. Clin Cancer Res 2012 1.61
29 The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proc Natl Acad Sci U S A 2010 1.45
30 18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers. Cancer Res 2011 1.36
31 Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clin Cancer Res 2008 1.25
32 Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. Proc Natl Acad Sci U S A 2011 1.21
33 Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death. Mol Syst Biol 2012 1.20
34 A mathematical methodology for determining the temporal order of pathway alterations arising during gliomagenesis. PLoS Comput Biol 2012 1.07
35 Akt phosphorylates the transcriptional repressor bmi1 to block its effects on the tumor-suppressing ink4a-arf locus. Sci Signal 2012 1.06
36 Integrin αvβ3-targeted IRDye 800CW near-infrared imaging of glioblastoma. Clin Cancer Res 2012 0.96
37 Epidermal growth factor receptor inhibitors in oncology. Curr Opin Oncol 2010 0.94
38 Inhibition of the phosphatidylinositol 3-kinase-Akt pathway enhances gamma-2 herpesvirus lytic replication and facilitates reactivation from latency. J Gen Virol 2009 0.94
39 Tracing cancer networks with phosphoproteomics. Nat Biotechnol 2010 0.90
40 Virchow 2011 or how to ID(H) human glioblastoma. J Clin Oncol 2011 0.81
41 Imaging tumor burden in the brain with 89Zr-transferrin. J Nucl Med 2012 0.80
42 TORward AKTually useful mouse models. Nat Med 2004 0.79
43 14-3-3sigma and p21 synergize to determine DNA damage response following Chk2 inhibition. Cell Cycle 2009 0.78
44 Cancer drug development. Preface. Curr Top Microbiol Immunol 2012 0.75